ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.
Former Karuna crew quickly assembles $225M for next neuro bet at Seaport
The team at Seaport Therapeutics, a Boston neuropsychiatry biotech, is having a good fall season. Seaport said Monday it has pieced together $225 million from